Osaka-Based Sakai Chemical Industrial Expands Contract Pharmaceutical Production
This article was originally published in PharmAsia News
Executive Summary
Osaka-based drug maker Sakai Chemical Industrial will boost its Nagano, Osaka factory's capacity and operation rates with plans to expand its contract drug production business. Currently contracted by four pharmaceutical companies, Sakai produces 10 therapeutic and 25 over-the-counter drugs, with 1 million solid preparations and 100,000 liquid formulations per month. Sakai plans to increase the capacity to 2 million solids and 500,000 liquids and increase to 10 contract companies. The company also plans to be manufacture sprays, oral solutions and health foods. The company expects the income from the contract production business will increase to ¥1 billion from several hundred thousand yen. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.